BARCELONA — The prevention and treatment of the growing problem of myopia will be in the spotlight here at the European Society of Retina Specialists 17th EURETINA Congress.
“Myopia is becoming an epidemic all over the world, especially in Asian countries,” said Anat Loewenstein, MD, from Tel Aviv University in Israel, who is general secretary of EURETINA.
During an update session, nonsurgical strategies to stop the progression of myopia will be discussed by Andrzej Grzybowski, MD, PhD, from the University of Warmia and Mazury in Olsztyn, Poland. And a new classification — pathological myopia — will be described by Kyoko Ohno-Matsui, MD, PhD, from Tokyo Medical and Dental University.
The use of atropine drops — among the most promising new treatments to slow the progression of myopia in children and adolescents — will be examined when researchers from the International Vision Correction Research Centre Network in Heidelberg, Germany, describe their experiences.
But myopia is only one of many hot topics in retina care that experts will explore during the meeting.
Diabetic Retinopathy
Diabetic retinopathy and how to determine the best treatment for each patient will be addressed during multiple sessions. “Which patient is suitable for which treatment? These days, this is the $1 million question that no one knows the answer to,” Dr Loewenstein told Medscape Medical News.
Data from clinical studies will be reported during breaking news sessions.
Twelve-month data from the PRIDE study, comparing ranibizumab with panretinal laser photocoagulation in the proliferative form of diabetic retinopathy, will be presented by Gabriele Lang, MD, from the University of Ulm in Germany.
Results from a network meta-analysis that incorporates patient-level data on diabetic macular edema, comparing vascular endothelial growth-factor (VEGF) inhibitors with laser photocoagulation, will be presented by Jean-François Korobelnik, MD, PhD, from the University Hospital Center of Bordeaux in France.
The cost-effectiveness of using optical coherence tomography to image all patients with diabetic retinopathy will be presented by Ian Wong, MD, from the University of Hong Kong. “This has a potentially huge impact on the work flow in our clinics,” Dr Loewenstein explained.
Dr Loewenstein said she is looking forward to a number of presentations in particular.
Retinal Vein Occlusion and Macular Degeneration
The one on robotic retinal vein cannulation for central retinal vein occlusion, by Peter Stalmans, MD, PhD, from Research Group Ophthalmology in Leuven, Belgium, “is going to be very exciting,” she said.
Also of interest, she pointed out, will be results from the CANTREAT trial, comparing a treat-and-extend strategy with monthly injections of ranibizumab for patients with neovascular age-related macular degeneration, and a new analysis of real-world data on ranibizumab from the LUMINOUS trial.
And new insights into dry age-related macular degeneration will be addressed, during a special session on emerging therapies, by Sascha Fauser, MD, from the University Hospital of Cologne in Germany.
A session on the fast-moving developments in uveal melanoma will explore how to distinguish choroidal nevi from melanoma and how to monitor suspicious lesions.
And data from the PLACE trial of patients with chronic central serous chorioretinopathy, comparing half-dose photodynamic laser treatment with high-density micropulse laser, will be presented by Camiel Boon, MD, PhD, from the Leiden University Medical Center in the Netherlands.
EURETINA excels at covering new surgical techniques, said Pravin Dugel, MD, from the University of Southern California in Los Angeles.
A bioengineering session — Where Surgery Meets Technology — “should be really good,” he told Medscape Medical News.
During this session, Dr Dugel will give an overview on informatics, such as augmented reality, in vitreoretinal surgery.
A talk on optimizing the use of ocular steroids, by Francine Behar-Cohen, MD, PhD, from the Jules-Gonin Eye Hospital in Lausanne, Switzerland, looks to be one of the most interesting presentations on the program, Dr Dugel said.
Dr Loewenstein has disclosed no relevant financial relationships. Dr Dugel reports relationships with 44 medical companies, including stock ownership in Clearside Bomedical, Digisight, Aerpio, Alimera, Annidis, Macusight, Ophthotech, PanOptica, and TrueVision.
Follow Medscape Ophthalmology on Twitter @MedscapeEye and Laird Harrison @LairdH
Tidak ada komentar:
Posting Komentar